Qayyum A, Oei EL, Paudel K, Fan SL. Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions. World J Nephrol 2015; 4(1): 92-97 [PMID: 25664250 DOI: 10.5527/wjn.v4.i1.92]
Corresponding Author of This Article
Dr. Stanley L Fan, Department of Renal Medicine and Transplantation, The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London E1 1BB, United Kingdom. s.fan@qmul.ac.uk
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Nephrol. Feb 6, 2015; 4(1): 92-97 Published online Feb 6, 2015. doi: 10.5527/wjn.v4.i1.92
Increasing the use of biocompatible, glucose-free peritoneal dialysis solutions
Ahad Qayyum, Elizabeth Ley Oei, Klara Paudel, Stanley L Fan
Ahad Qayyum, Klara Paudel, Stanley L Fan, Department of Renal Medicine and Transplantation, The Royal London Hospital, Barts Health NHS Trust, London E1 1BB, United Kingdom
Elizabeth Ley Oei, Department of Renal Medicine and Transplantation, Singapore General Hospital, Singapore 169608, Singapore
Author contributions: Qayyum A and Fan SL designed the mini-review, generated the tables and figure and co-wrote the manuscript; Oei EL and Paudel K contributed to the data collection and writing of the manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Stanley L Fan, Department of Renal Medicine and Transplantation, The Royal London Hospital, Barts Health NHS Trust, Whitechapel, London E1 1BB, United Kingdom. s.fan@qmul.ac.uk
Telephone: +44-20-35942674 Fax: +44-20-35942691
Received: June 14, 2014 Peer-review started: June 15, 2014 First decision: September 28, 2014 Revised: October 7, 2014 Accepted: November 17, 2014 Article in press: November 19, 2014 Published online: February 6, 2015
Core Tip
Core tip: There is increasing evidence of benefit for using biocompatible and non-glucose based peritoneal dialysis (PD) fluids. However, cost remains an impediment and perhaps there are selected groups of patients where the cost can be justified. We suggest that biocompatible solutions should be considered for patients with residual renal function and/or expected to remain on PD for a long period. They are particularly helpful for patients with drain-in pains. The targeting of diabetic patients for non-glucose solutions is intriguing given the recent IMPENDIA/EDEN study although vigilance is required to minimize unaware hypoglycemia. It remains to be seen if PD nephrologists are willing to take the same leap of faith that our hemodialysis (HD) colleagues took when they moved from Acetate-based HD solutions to Bicarbonate dialysate. It is possible that economies of scale will reduce the cost of the biocompatible solutions if we use them more frequently.
